Table 1. Baseline and immunologic characteristics of the patient populations.
| ABOi KT (n = 58) | ABOi+HLAs (n = 12) | HLAs (n = 22) | CONT (n = 292) | |
|---|---|---|---|---|
| Age (year) | 44.6 ± 10.1 | 45.0 ± 10.5 | 46.1 ± 8.8 | 44.0 ± 12.0 |
| Male, n (%) | 42 (72.4) † , ‡ , § | 3 (25.0) *, § | 6 (27.3) *, § | 170 (58.2) *, ‡ |
| F/U month | 24.8 ± 16.3 ‡ | 27.8 ± 12.2 | 31.3 ± 14.4 *, § | 24.5 ± 9.5 ‡ |
| PRD, n (%) | ||||
| Chronic GN | 21 (36.2) | 4 (33.3) | 8 (36.4) | 84 (28.8) |
| DM | 13 (22.4) | 4 (33.3) | 5 (22.7) | 54 (18.5) |
| HTN | 13 (24.5) | 0 | 25 (19.4) | 29 (9.9) |
| ADPKD | 2 (3.4) | 0 (0.0) | 0 (0.0) | 7 (2.4) |
| SLE | 1 | 0 (0.0) | 0 (0,0) | 10 (3.4) |
| Unknown | 15 (25.9) | 4 (33.3) | 5 (22.7) | 108 (37.0) |
| HLA mismatch | 3.8 ± 1.5 § | 3.3 ± 1.2 | 3.6 ± 1.5 § | 2.7 ± 1.9 * , ‡ |
| LRD, n (%) | 32 (55.2) § | 6 (50.0) | 17 (77.3) | 212 (72.6) * |
| Re-transplant, n (%) | 7 (12.0) † , ‡ | 5 (41.7) *, § | 8 (36.3) § | 26 (8.9) † , ‡ |
| PRA >50%, n (%) | 8 (13.8) † , ‡ | 11 (91.7) *, § | 18 (81.8) *, § | 34 (11.6) † , ‡ |
| Positive XM, n (%) | 0 (0.0) † , ‡ | 10 (83.3) *, § | 19 (86.4) *, § | 0 (0.0) † , ‡ |
| RTX dose | † , ‡ , § | § | * , § | *, † , ‡ |
| Not done | 0 | 0 | 0 | 258 (88.4) |
| 100 mg/m2, n (%) | 37 (64) | 0 (0) | 0 (0) | 0 |
| 375 mg/m2, n (%) | 21 (36) | 12 (100) | 22 (100) | 34 (11.6) |
| Number of PP/IVIg | 6.0±3.4 | 7.0±2.8 | 5.5±2.2 | 0030 |
ABOi, ABO incompatible; HLAs, sensitized to HLA; CONT, control; F/U, follow up; GN, glomerulonephritis; DM, diabetes mellitus; HTN, hypertension; ADPKD, autosomal dominant polycystic kidney disease; SLE, systemic lupus nephritis; LRD, living related donor; PRA, panel reactive antibody; XM, crossmatch; RTX, rituximab; PP, plasmapheresis; IVIg, intravenous immunoglobulin, CONT, control
* P<0.05 vs. ABOi
† P<0.05 vs. ABOi+HLAs
‡ P<0.05 vs. HLAs
§ P<0.05 vs. CONT.